Baricitinib is a Janus kinase 1/2 inhibitor the has been shown to decrease mortality in COVID-19 patients who are on HFNC or NIV.
Show Notes: https://eddyjoemd.com/baricitinib-covid/
Although great care has been taken to ensure that the information in this podcast are accurate, eddyjoe, LLC shall not be held responsible or in any way liable for the continued accuracy of the information, or for any errors, omissions or inaccuracies, or for any consequences arising therefrom.
Website: www.eddyjoemd.com
Instagram: www.instagram.com/eddyjoemd
Twitter: www.twitter.com/eddyjoemd
Facebook: www.facebook.com/eddyjoemd
Podcast: https://anchor.fm/eddyjoemd
My Amazon store for resources you may find helpful: www.amazon.com/shop/eddyjoemd 
Citation: RECOVERY Collaborative Group. Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): a randomised, controlled, open-label, platform trial. Lancet. 2021 May 1;397(10285):1637-1645. doi: 10.1016/S0140-6736(21)00676-0. PMID: 33933206; PMCID: PMC8084355.

---

This episode is sponsored by
· Anchor: The easiest way to make a podcast. https://anchor.fm/app

Support this podcast: https://anchor.fm/eddyjoemd/support